Ligands in signaling pathways
Status: incomplete, handed off mid-way. See Handoff for what is done, what is
next, and how to rerun everything.
Bottom line: GO treats a protein ligand as part of the signaling pathway it starts, and
human and fly curators annotate it that way. That gives a simple completeness test: every
receptor-initiated pathway an organism annotates should contain at least one gene with
receptor ligand activity. Run on seven GO Consortium GAFs, the test fails for a third or more
of the pathway terms in every organism. Most failures have no protein ligand to find (small
molecules, light, microbial products, antigens). The rest are real gaps: ligands missing from
their pathway, ligands placed only on a neighbouring term, and ligands that carry a
receptor-specific binding term (such as "Roundabout binding") instead of a ligand-activity term.
Knowing that some ligand is missing needs only GOA. Knowing which ligand is missing is
curated knowledge, and the curated module is the place to keep it with its evidence. We
therefore started curating pan-species signaling modules whose first step is the ligand, so
that generic pathway hole-filling can report the gaps. Three new two-step modules are done
(netrin, Slit-Robo, and MIF-CD74/CD44) and two existing modules with open ligand gaps were upgraded
to family-level ligand steps (Kit signaling and Ephrin-Eph signaling).
1. Are ligands part of the pathway in GO?
Yes, in standard annotation and in the ontology.
- Annotations. A hand-picked sample of textbook ligands was checked against QuickGO
(results/ligand_survey.json,
script). 23 of 24 human
ligands (plus 4 of 5 receptor comparators) and all 14 fly ligands are annotatedinvolved_in
the pathway they activate, mostly
with experimental evidence (FlyBase almost entirely so). Human KITLG is the exception: it has
no Kit signaling pathway annotation. Receptors are annotated the same way, except the
inhibitory receptors PTCH1 and ptc, which carry only regulation terms. - Fission yeast is different. PomBase annotates the pheromones map2 and mfm1-3, the
receptors mam2 and map3, and the G-alpha gpa1 alike to positive regulation of pheromone
response MAPK cascade; only the kinases areinvolved_inthe cascade. The old pathway term
(pheromone-dependent signal transduction involved in conjugation with cellular fusion) is
obsolete. We want one convention across GO, so this is a convention to raise, not to model
around. - Ontology. Receptor ligand activity (GO:0048018) is
part_ofsignal transduction
(GO:0007165), whose definition says it "begins with reception of a signal (e.g. a ligand
binding to a receptor…)". The GO-CAM signaling receptor guideline (reviewed 2023-07-20) says
a ligand "'enables' receptor ligand activity (GO:0048018) or a child" and is "'part of' the
process in which the ligand participates". - The "cellular response to X" question is open. Since 2014 pathway terms are
part_of
the matching cellular response to X stimulus term, so a ligand in the pathway is, by
inference, in the response. Whether ligands should carry the response term is unresolved in
go-ontology#15477 (2018); R.
Lovering and P. Gaudet said there that the ligand belongs in the pathway. The link is applied
unevenly: for example vascular endothelial growth factor signaling pathway is part of the
VEGF response, but vascular endothelial growth factor receptor signaling pathway is not.
Earlier history: #5890 (2009),
#10067 (2012, is_a), then a
2014-12-20 move to part_of.
2. Ligand activity versus receptor binding terms
A background research pass (go-ontology issues, GO docs, QuickGO term history) found that
annotating ligands only with "X receptor binding" terms is history, not policy:
- GO's written guidance is to annotate a ligand to receptor ligand activity or a child. No
guideline gives the receptor-specific binding terms a role for ligands. - In January 2026
(go-ontology#31015, PR #31370)
receptor ligand activity changed from "a kind of signaling receptor binding" to "has
signaling receptor binding as a part", so that ligand activity is "classed as an activity
rather than binding only" (V. Wood). Since then a ligand annotated only to, say, Roundabout
binding no longer counts as a ligand. That is why these gaps are now visible. - The receptor-specific terms (Notch binding, frizzled binding, patched binding date from
2001) are old and not scheduled for replacement; a 2022 request for a ligand-binding branch
(#23891) was closed as not planned. - They are noisy: netrin receptor binding is annotated only to receptor-side proteins (DSCAM,
tubulins) and to no netrin; Notch binding sits on ADAM17, DTX1 and numb; patched binding
on SMO. - The comment on signaling receptor binding (GO:0005102) still points to "receptor agonist
activity", a name retired in 2017. No open issue covers this. - Hedgehog is an awkward case: Hh binding inhibits Patched, while receptor ligand activity is
now classed as an activator. #14275
(open since 2017, agonist vs antagonist ligand terms) is the natural place to raise it.
Undecided; parked.
Decisions taken (C. Mungall, this session):
- A module's ligand step uses receptor ligand activity or a fitting child (for example
chemorepellent activity), not the receptor-specific binding term. - Keep the PANTHER family and PAINT ancestral node on the ligand step with the correct term,
and record in the family review that the PAINT node's binding term should be the
ligand-activity term. - Modules are pan-species; species proteins are representative examples only.
- Receptor-specific binding terms in gene reviews should generally be MODIFY. The replacement
depends on the protein: ligands go to receptor ligand activity or a child; non-ligands that
bind a receptor need their real activity (adaptor, enzyme, and so on). Adaptor terms that GO
places under signaling receptor binding (such as transmembrane receptor protein tyrosine
kinase adaptor activity) are already activities and are excluded.
3. The ligand gap check
Rule. For each organism, every pathway term P under cell surface receptor signaling
pathway (GO:0007166) or G protein-coupled receptor signaling pathway (GO:0007186) that the
organism's GAF uses directly must contain a gene that is involved_in P (or a subterm) and
enables receptor ligand activity (or a subterm). GPCR pathways are added separately because
they are not under cell surface receptor signaling. The check uses only GOA and the ontology:
no modules, no hand-picked lists.
Full output: results/RESULTS.md (generated). Summary
for the GAFs dated 2026-05-21 and GO release 2026-07-26:
| Organism | Pathway terms used | No ligand gene |
|---|---|---|
| human | 237 | 78 |
| mouse | 234 | 86 |
| rat | 231 | 79 |
| zebrafish | 145 | 91 |
| fly | 74 | 39 |
| budding yeast | 6 | 6 |
| fission yeast | 4 | 4 |
Triage. scripts/triage.py sorts each failure.
Where a term passes in another species of the same lineage, that species' ligands are looked up
by gene symbol in the failing species. Where no species passes, an expected-ligand list is used.
Both curated inputs are explicit files, so the prior knowledge is visible and reviewable:
- curated/term_labels.yaml: terms with no host
protein ligand (X: small molecule, light, microbial; Y: antigen, contact, ligand-independent). - curated/expected_ligands.yaml: expected
ligands per term. Each entry is a candidate ligand step for a module. - curated/organism_flags.yaml: suspect
over-annotations (O) and misapplied or generic terms (G).
| Category | human | mouse | rat | zebrafish | fly |
|---|---|---|---|---|---|
| A: ligand counterpart not on the pathway | 11 | 10 | 13 | 29 | 5 |
| B: ligand only on a related pathway term | 8 | 9 | 9 | 7 | 1 |
| C: ligand on the pathway but no ligand-activity MF | 4 | 4 | 4 | 8 | 2 |
| X/Y: no host protein ligand expected | 48 | 51 | 45 | 39 | 21 |
| O: suspect over-annotation | 0 | 0 | 0 | 0 | 6 |
| Other (N, U, G) | 7 | 12 | 8 | 8 | 4 |
Examples (human unless noted). A: KITLG, IL21, IL22, CXCL8, C5, MIF, FASLG and the netrins are
not on their pathways. B: VEGFA/VEGFB/PGF are on VEGF receptor signaling but not the VEGFR-1
subterm; the FGFs are on FGF receptor signaling but not its "involved in X" subterms; fly spz5
and NT1 are only on Toll signaling, not neurotrophin signaling. C: IL34 and the collagens are in
their pathways without a ligand MF; fly Ephrin and sli likewise. O (fly; from background
knowledge, not checked): NGF, neurotrophin TRK, G-CSF, adiponectin, TLR4 and LPS-mediated
signaling terms in a genome without those ligands or receptors.
Before the triage was automated, 28 human and fly failures were sorted by hand into A, B or C.
The automatic lookup agrees on 21. The differences: three FGF "involved in X" subterms have no
donor (U); the FGF receptor apoptotic signaling term comes out C because FGFR3 itself carries a
ligand-activity MF in another species; and three fly cases that are really B (egr, Ilps,
spz5/NT1 sit on a sibling pathway) come out A because the sibling shares only generic ancestors.
(X, Y, O and G agree by construction, since the hand labels are the curated inputs.)
Reverse check. Ligand-activity genes in no signaling pathway: 22 of 571 in human (mostly
chemokines such as CCL17, CCL27, CCL28, CXCL2, CXCL3, CXCL16, PPBP, PF4V1, and beta-defensins;
ALKBH1 and DPP4 look like MF over-annotation), 1 in fly (orion), none in either yeast. In
budding yeast the receptors STE2/STE3 are in the pheromone pathway but the pheromones are not.
Relaxing the rule does not work. Counting genes with a signaling receptor binding MF plus
an extracellular CC annotation as ligands makes 31 more human terms and 3 more fly terms pass,
almost all falsely: G-protein alphas, LYN and IRAK4 qualify through exosome or extracellular
annotations, and netrin signaling "passes" on DSCAM and tubulin. Only IL34 (human) and sli
(fly) are real. The ligand step has to come from curated modules.
Caveats: symbol matching stands in for orthology; budding yeast and fission yeast have no
same-lineage donor in the seven-species panel (so unflagged yeast terms fall into U);
go-basic omits MF-to-BP part_of links, which is harmless here because only BP annotations
place genes in pathways.
4. Curated modules
All eighteen modules have family-grounded pan-species ligand steps and pass the schema and module
validators.
- Netrin signaling (netrin-activated signaling
pathway). Ligand: netrin family (PANTHER netrin/laminin familyPTHR10574, restricted to
canonical secreted netrins under PAINT node PTN008501429 and excluding netrin-G1/G2,
netrin-4, and netrin-5), receptor ligand activity (netrins both attract and repel, so neither
child fits). Receptor: attraction through the DCC family (no PANTHER id; DCC and Frazzled sit
in different subfamilies of a broad family) or repulsion through the UNC5 family. GOA gaps
recorded in the notes: no netrin and not DCC is on the netrin pathway in human; fly NetA/NetB
are only on axon guidance terms and have no MF. - Slit-Robo signaling (Roundabout signaling
pathway). Ligand: Slit subfamilies of PTHR45836, chemorepellent activity, with PAINT node
PTN002911633 kept. The module validator warns that this node's IBD rows are heparin binding
and Roundabout binding (GO:0048495) only, so the node cannot be the evidence for the step's
chemorepellent activity, location or process terms; the mismatch is intentional (Decision 2)
and documented in the PTHR45836 family review. Receptor: Robo receptors (no PANTHER id; they span three
families). GOA gaps in the notes: human SLIT1 and ROBO2, fly robo2 and robo3 are not on the
pathway. - Kit signaling (Kit signaling pathway,
GO:0038109).
Upgraded the ligand step (kitlg_scf_ligand) from a single-geneGENE_PRODUCTselector toFAMILY
(PANTHER:PTHR11574KIT LIGAND, PAINT nodePTN002611905, cytokine activity
GO:0005125) with representative members in human (KITLG) and zebrafish (kitlga; the
PTHR11574family review also covers mouseKitlgand zebrafishkitlgb). GOA gaps resolved
in gene reviews: humanKITLGand zebrafishkitlgalackedGO:0038109Kit signaling
pathway (added asNEWin both reviews). - Ephrin-Eph signaling (ephrin receptor
signaling pathway,GO:0048013). Upgraded the ligand step (nowephrin_ligand_family, formerly
the EFNB2-specificefnb2_efnb2_ligand) from a single-geneGENE_PRODUCTselector using ephrin
receptor binding (GO:0046875) toFAMILY
(PANTHER:PTHR11304EPHRIN, PAINT nodePTN000885159, receptor ligand activity
GO:0048018) with representative members on the module step for human (EFNB2,EFNB1) and
zebrafish (efnb2a), while thePTHR11304family review spans GPI-anchored ephrin-A
(EFNA1–EFNA5), transmembrane ephrin-B (EFNB1–EFNB3), C. elegans (efn-4), and
Drosophila (Ephrin).PTN000885159is kept on the ligand step although its IBD MF is
GO:0046875rather thanGO:0048018(Decision 2); the mismatch is documented in
interpro/panther/PTHR11304/PTHR11304-review.yaml. The module validator does not flag it. Ephrin
reverse signaling (into the ephrin-expressing cell) is outside the module boundary. - MIF-CD74/CD44 signaling (macrophage migration inhibitory
factor signaling pathway,GO:0035691). Two-step module scoped to Euteleostomi, the clade where
both receptor subunits exist (the CD74 and CD44 PAINT nodesPTN002679661andPTN002566805are
both placed there); the MIF ligand family is older (Bilateria nodePTN000237513, Eukaryota root
PTN000237510). Ligand: MIF / D-dopachrome tautomerase family (PANTHER:PTHR11954), cytokine
activity (GO:0005125, a child of receptor ligand activityGO:0048018). Receptor: the
macrophage migration inhibitory factor receptor complex (GO:0035692), cytokine receptor
activity (GO:0004896), with CD74 (PANTHER:PTHR14093:SF17) as the MIF-binding unit
(macrophage migration inhibitory factor binding,GO:0035718) and CD44
(PANTHER:PTHR10225:SF6) as the signaling unit; CD74 alone binds MIF but cannot signal. GOA gap resolved in the new humanMIFgene
review: in GOA only the receptorCD74carriedGO:0035691, while humanMIFcarried
GO:0005125cytokine activity and the parent termGO:0007166cell surface receptor
signaling pathway (IDA,PMID:12782713), which is refined viaMODIFYtoGO:0035691
macrophage migration inhibitory factor signaling pathway. - IL-34-CSF1R signaling (interleukin-34-mediated signaling
pathway,GO:0061514). Two-step pan-species module (IL-34 ligand step, CSF1R receptor step).
Macrophage colony-stimulating factor signaling pathway (GO:0038145) is not a module concept,
because it is defined by CSF1 binding; downstream CSF1R effectors (GRB2, PI3K, PLCG2, MAPK,
STAT3) are left for a future CSF1R module. Ligand: IL-34 family (PANTHER:PTHR28606, PAINT
nodePTN002823014), cytokine activity (GO:0005125). Receptor: CSF1R subfamily
(PANTHER:PTHR24416:SF47, PAINT nodesPTN001230349andPTN002814394), macrophage
colony-stimulating factor receptor activity (GO:0005011). GOA Category C gap resolved in the
new humanIL34gene review: in GOAIL34was annotated toGO:0038145(NAS, modified to
GO:0061514) andGO:0061514(IDA), while its only MF terms wereGO:0005157(macrophage
colony-stimulating factor receptor binding,IBA/IDA/IEA) andGO:0005515(protein
binding,IPI);GO:0005157is modified toGO:0005125(cytokine activity) per Decision 2. - IL-21 signaling (interleukin-21-mediated signaling
pathway,GO:0038114). Three-step pan-species module. Ligand: IL-21 subfamily
(PANTHER:PTHR14356:SF2, withinPANTHER:PTHR14356INTERLEUKIN-15-RELATED, PAINT nodes
PTN002682898andPTN007637558, which attest only biological-process terms, so they do not
ground the step's MF or location;PTN002682898has no taxon inPTHR14356-paint.tsv),
cytokine activity (GO:0005125). Receptor: IL21R subfamily (PANTHER:PTHR23037:SF7, PAINT
nodePTN000547990), interleukin-21 receptor activity (GO:0001532), paired with the common
gamma chain (IL2RG,PANTHER:PTHR23037:SF47, PAINT nodesPTN002745476andPTN008588077),
cytokine receptor activity (GO:0004896). GOA Category A gap resolved in the humanIL21
gene review:IL21lackedGO:0038114and carriedGO:0007165(signal transduction,NAS,
refined viaMODIFYtoGO:0038114) alongsideGO:0007259(cell surface receptor signaling
pathway via JAK-STAT,NAS,ACCEPT), and its receptor-binding annotations (GO:0005126,
GO:0005134) are modified toGO:0005125(cytokine activity). - IL-22 signaling (interleukin-22-mediated signaling
pathway,GO:0140865). Pan-species module. Ligand: IL-22 family (PANTHER:PTHR48488,
PAINT nodePTN009232695), cytokine activity (GO:0005125). Receptor: IL22RA1 subfamily
(PANTHER:PTHR20859:SF53, PAINT nodePTN000466212), interleukin-22 receptor activity
(GO:0042018), paired with the sharedIL10RBbeta chain (PANTHER:PTHR20859:SF50), cytokine
receptor activity (GO:0004896). The soluble decoy receptorIL22RA2(PANTHER:PTHR20859:SF51)
is outside the module boundary and recorded in a boundary note, not as a part. GOA Category A
gap resolved in the humanIL22gene review:IL22lackedGO:0140865and carried only
GO:0007165(signal transduction,IEA), refined viaMODIFYtoGO:0140865(withNEW
GO:0007259cell surface receptor signaling pathway via JAK-STAT retained alongside it), and
GO:0045518(interleukin-22 receptor binding,NAS) is modified toGO:0005125(cytokine
activity). - Death receptor / Fas signaling (Fas
signaling pathway,GO:0036337, and extrinsic apoptotic signaling pathway via death domain
receptors,GO:0008625). Converted the three remaining single-geneGENE_PRODUCTselectors to
FAMILY, so every step is family-grounded. Ligand: Fas ligand subfamily (PANTHER:PTHR11471:SF33, withinPANTHER:PTHR11471
TUMOR NECROSIS FACTOR FAMILY MEMBER, PAINT nodePTN000895255), cytokine activity
(GO:0005125). Receptor: FAS (PANTHER:PTHR46874:SF1); DISC adaptor: FADD
(PANTHER:PTHR15077:SF10); initiator protease: CASP8 (PANTHER:PTHR10454, PAINT node
PTN000047947).
GOA Category A gap resolved in the humanFASLGgene review:FASLGcarriedGO:0008625
(extrinsic apoptotic signaling pathway via death domain receptors) andGO:0005125(cytokine
activity) but lackedGO:0036337(Fas signaling pathway), added asNEW(PMID:7826947). - Chemokine / Interleukin-8 signaling
(chemokine-mediated signaling pathway,GO:0070098, and interleukin-8-mediated signaling
pathway,GO:0038112). Converted the four remaining single-geneGENE_PRODUCTselectors to
FAMILY, so every step is family-grounded. Ligand: Interleukin-8 subfamily (PANTHER:PTHR12015:SF200, withinPANTHER:PTHR12015
SMALL INDUCIBLE CYTOKINE A, PAINT nodePTN002564680), chemokine activity (GO:0008009).
Receptor: CXCR2 (PANTHER:PTHR10489:SF689, PAINT nodesPTN001628461andPTN002573743) and
CCR5 (PANTHER:PTHR10489:SF686, PAINT nodePTN001628461). In the new humanCXCL8gene
review,CXCL8already carriesGO:0038112(interleukin-8-mediated signaling pathway,IDA,
PMID:8399143) andGO:0008009(chemokine activity) in GOA, both of which areACCEPTed;
broader or sibling signaling rows (GO:0007165,GO:0007186,GO:0035556,GO:0019722) are
refined viaMODIFYtoGO:0038112,GO:0005125(cytokine activity) is modified to
GO:0008009(chemokine activity), andGO:0005153(interleukin-8 receptor binding) is
ACCEPTed (withGO:0045236CXCR chemokine receptor binding modified toGO:0005153). - Complement component C5a signaling (complement component
C5a signaling pathway,GO:0038178). Three-step pan-species module. Ligand: Complement C5
subfamily (PANTHER:PTHR11412:SF83, withinPANTHER:PTHR11412MACROGLOBULIN / COMPLEMENT,
PAINT nodePTN002605305), G protein-coupled receptor binding (GO:0001664). Receptors: C5AR1
(PANTHER:PTHR24225:SF29) and C5AR2 (PANTHER:PTHR24225:SF1), complement receptor activity
(GO:0004875). GOA Category A gap resolved in the new humanC5gene review:C5lacked
GO:0038178in GOA (added viaNEWwithPMID:36806352andMODIFYonGO:0007166
PMID:10820279andGO:0007186PMID:8898085),GO:0001664(G protein-coupled receptor
binding) isACCEPTed as the core MF (withGO:0005102modified toGO:0001664), while the
mis-curatedPINCTASGO:0008009(chemokine activity,PMID:10820279) and InterPro2GO
IEAGO:0004866(endopeptidase inhibitor activity, also over-propagated at PAINT node
PTN000892454) are removed (REMOVE, withsource_defectsonGO:0008009). - Thyroid-stimulating hormone (TSH) signaling (thyroid-stimulating
hormone signaling pathway,GO:0038194). Two-step pan-species module. Ligand: TSH
heterodimer composed of TSHB (PANTHER:PTHR11515:SF5, withinPANTHER:PTHR11515GLYCOPROTEIN HORMONE BETA CHAIN, PAINT nodePTN000162063) and CGA (PANTHER:PTHR11509:SF0, within
PANTHER:PTHR11509GLYCOPROTEIN HORMONES ALPHA CHAIN, PAINT nodePTN002608947), hormone
activity (GO:0005179) and signaling receptor binding (GO:0005102). Receptor: TSHR
(PANTHER:PTHR24372:SF0), thyroid-stimulating hormone receptor activity (GO:0004996). GOA
Category A gap resolved in the new humanTSHBandCGAgene reviews (NEWGO:0038194on
both subunits andMODIFYonGO:0007186→GO:0038194onTSHB). - Bombesin receptor signaling (bombesin receptor
signaling pathway,GO:0031989). Two-step pan-species module. Ligands: GRP
(PANTHER:PTHR16866:SF2) and NMB (PANTHER:PTHR16866:SF3, withinPANTHER:PTHR16866
GASTRIN-RELEASING PEPTIDE, PAINT nodePTN008565241), neuropeptide hormone activity
(GO:0005184; with receptor-specific binding terms gastrin-releasing peptide receptor binding
GO:0031709and neuromedin B receptor bindingGO:0031710under bombesin receptor binding
GO:0031705). Receptors: GRPR (PANTHER:PTHR45695:SF7), NMBR (PANTHER:PTHR45695:SF8), and BRS3
(PANTHER:PTHR45695:SF6), bombesin receptor activity (GO:0004946). GOA Category A gap
resolved in the new humanGRPandNMBgene reviews (NEWGO:0031989on both genes,
retaining complementaryGO:0007218neuropeptide signaling pathway asACCEPT, plusMODIFYon
GO:0007165→GO:0031989andGO:0007218on both genes,MODIFYonGO:1900738→GO:0007200
onGRP, andMODIFYonGO:0005179→GO:0005184onNMB). - Collagen-DDR signaling (collagen-activated
tyrosine kinase receptor signaling pathway,GO:0038063). Scoped to Eumetazoa, the taxon of
the receptor PAINT node. Ligand: a variant set by collagen class, each with receptor ligand
activity (GO:0048018), since no child term fits a structural collagen acting as a ligand:
fibrillar collagens I-III for both receptors and collagen IV for DDR1 (both in
PANTHER:PTHR24023COLLAGEN ALPHA, restricted to these chains), collagen X for DDR2
(PANTHER:PTHR15427:SF48). Drosophila Multiplexin, known only from a genetic interaction, is in
the notes and the knowledge gap, not a ligand variant (the same bar that keeps Toll-2 out of
the neurotrophin module). Receptor: DDR1 and DDR2
(DDR subfamilies ofPANTHER:PTHR24416, PAINT nodePTN002400507), protein tyrosine
kinase collagen receptor activity (GO:0038062). Fly Ddr is not a representative: its gene
review finds dipteran Ddr is a predicted pseudokinase (lost catalytic lysine, catalytic-loop
asparagine and DFG aspartate) with an unconserved collagen pocket, while Tribolium DDR and
C. elegans ddr-2 keep all three kinase residues (the honeybee model keeps two; C. elegans ddr-1 one). Downstream effectors and the other collagen
receptors (integrins, GP6, LAIR1, which belong to collagen-activated signaling pathway) are
boundary notes. GOA gaps recorded in the notes: in human only COL4A2 and COL4A6 are on the
pathway (IBA) and no collagen has a ligand-activity MF in GOA (resolved for humanCOL1A1in its
updated gene review viaNEWICannotations and a second core function forGO:0048018and
GO:0038063backed byReactome:R-HSA-2327738andReactome:R-HSA-2465890, alongside
interpro/panther/PTHR24023/PTHR24023-review.yaml); in fly no collagen is on the pathway.
No paper shows that fly collagen IV activates Ddr, which is recorded as a biology knowledge gap. - Neurotrophin signaling through Toll-family receptors
(neurotrophin signaling pathway,GO:0038179). Scoped to Drosophila melanogaster, because no
cached paper tests the ligand-receptor pairing in other insects. Ligand: the neurotrophins DNT1
(NT1) and DNT2 (spz5) (PANTHER:PTHR23199NEUROTROPHIN 1-RELATED, PAINT nodePTN002354018),
growth factor activity (GO:0008083, a child of receptor ligand activity). Receptor: Toll-6 and
Toll-7, neurotrophin receptor activity (GO:0005030); no PANTHER id, as they sit in different
families. Optional co-receptor: Kek-6 (PANTHER:PTHR24366:SF87, PAINT nodePTN008615184).
Adaptors (MyD88, Wek, Sarm) and JNK/NF-kB outputs are a boundary note, as is the immune
Spaetzle-Toll-1 pathway (dmel_toll_signaling). GOA gap recorded in the notes: NT1 and spz5 are
annotated only to Toll signaling pathway, not to the neurotrophin pathway. The notes also flag
that Toll-6 inherits Roundabout binding and axon-guidance IBAs from the Slit PAINT nodes, the
over-propagation the PTHR45836 family review already records for its Toll-6 subfamily. - Endothelin receptor signaling (endothelin
receptor signaling pathway,GO:0086100, and phospholipase C-activating endothelin receptor
signaling pathway,GO:0160135). Two-step pan-species module. Ligands: EDN1
(PANTHER:PTHR13874:SF10), EDN2 (PANTHER:PTHR13874:SF9), and EDN3 (PANTHER:PTHR13874:SF11,
withinPANTHER:PTHR13874ENDOTHELIN, PAINT nodePTN000356323), hormone activity
(GO:0005179;PTN000356323also propagates endothelin B receptor binding,GO:0031708).
Receptors: EDNRA (PANTHER:PTHR46099:SF2) and EDNRB (PANTHER:PTHR46099:SF3), endothelin
receptor activity (GO:0004962). GOA Category B/A gaps resolved in the new humanEDN1and
EDN3gene reviews (EDN1accepts existingGO:0086100,GO:0005179,GO:0031707, and
GO:0031708, addsNEWICGO:0160135, modifiesGO:0007166,GO:0007186,GO:0007267,
GO:0023019,GO:0035556, andGO:0160195→GO:0086100andGO:0160135, and modifies
GO:0005102andGO:0048018→GO:0005179,GO:0031707, andGO:0031708;EDN3addsNEW
IDAGO:0086100,GO:0160135,GO:0031707, andGO:0007204, accepts existingGO:0005179
andGO:0031708, modifiesGO:0007165,GO:0007166, andGO:0007267→GO:0086100and
GO:0160135, and modifiesGO:0005102→GO:0031708andGO:0031707). - Galanin-activated signaling (galanin-activated
signaling pathway,GO:0090663). Two-step pan-species module. Ligands: GAL
(PANTHER:PTHR16839:SF1, PAINT nodePTN008359337) and GALP (PANTHER:PTHR20950:SF1, PAINT node
PTN001463568), neuropeptide hormone activity (GO:0005184). Receptors: GALR1
(PANTHER:PTHR24230:SF31), GALR2 (PANTHER:PTHR24230:SF13), and GALR3
(PANTHER:PTHR24230:SF17), galanin receptor activity (GO:0004966). GOA Category A gap resolved in the new humanGALandGALPgene reviews (GAL
addsNEWICGO:0090663, retainsGO:0005184,GO:0007218neuropeptide signaling
pathway, andGO:0031764/GO:0031765/GO:0031766asACCEPT, and modifiesGO:0007165and
GO:0045944→GO:0090663,GO:0005179→GO:0005184, andGO:0004966→GO:0005184,
GO:0031764, andGO:0031765;GALPaddsNEWISSGO:0090663andGO:0005184from rat
GalpUniProtKB:Q9QXQ6, modifiesGO:0007165→GO:0090663andGO:0005179→GO:0005184,
and retainsGO:0005576asACCEPT). - Opioid receptor signaling (G protein-coupled
opioid receptor signaling pathway,GO:0038003, and adenylate cyclase-inhibiting opioid receptor
signaling pathway,GO:0031635). Two-step pan-species module. Ligands: PENK
(PANTHER:PTHR11438:SF3), PDYN (PANTHER:PTHR11438:SF4), and PNOC (PANTHER:PTHR11438:SF2,
withinPANTHER:PTHR11438PROENKEPHALIN, PAINT nodePTN000153716), opioid peptide activity
(GO:0001515). Receptors: OPRM1 (PANTHER:PTHR24229:SF7), OPRD1 (PANTHER:PTHR24229:SF2),
OPRK1 (PANTHER:PTHR24229:SF1), and OPRL1 (PANTHER:PTHR24229:SF11), G protein-coupled opioid
receptor activity (GO:0004985). GOA Category B/A gaps resolved in the new humanPENKandPDYN
gene reviews (PENKaccepts existingGO:0038003,GO:0001515,GO:0005184,GO:0031628, and
GO:0007218, addsNEWICGO:0031635, and modifiesGO:0007165→GO:0038003and
GO:0031635andGO:0048018→GO:0001515andGO:0005184;PDYNaddsNEWIDA
GO:0038003andNEWICGO:0031635and accepts existingGO:0001515,GO:0031628, and
GO:0007218).
5. Other curator work in this branch
- NTN1 and NTN3 gene reviews: core function and MODIFY replacements changed from netrin
receptor binding to receptor ligand activity, andNEWannotations for netrin-activated
signaling pathway (GO:0038007) added to both reviews and theircore_functions. NTN1's
four non-verbatim deep-research quotes (listed inconf/local_quote_baseline.yaml) replaced
with row-specific verbatim publication quotes and their baseline entries removed. The repo-wide
prune would also remove 233 now-passing entries for other genes; that was left out to keep this
change focused. - KITLG, kitlga, EFNB1, and MIF gene reviews: added
NEWGO:0038109(Kit signaling
pathway) to humanKITLGand zebrafishkitlga(inkitlga, cytokine activity is carried
by theMODIFYofGO:0005173stem cell factor receptor binding, not by a separateNEWrow);
updatedGO:0046875(ephrin receptor binding) toMODIFY→GO:0048018(receptor ligand
activity) on humanEFNB1, with the five protein binding rows recording EFNB1–Eph receptor
pairs alsoMODIFY→GO:0048018, the ERBB2 rows →GO:0005102(not a ligand interaction),
the PICK1 row →GO:0030165PDZ domain binding, and the ANKRD46 two-hybrid rowREMOVE; and
created the full humanMIFreview (genes/human/MIF/MIF-ai-review.yaml) withMODIFYon
GO:0007166(cell surface receptor signaling pathway) →GO:0035691(macrophage migration
inhibitory factor signaling pathway) andMODIFYonGO:0005126(cytokine receptor
binding) →GO:0005125(cytokine activity). - IL34, IL21, and IL22 gene reviews: created the human
IL34review
(genes/human/IL34/IL34-ai-review.yaml), modifyingGO:0005157(macrophage colony-stimulating
factor receptor binding) toGO:0005125(cytokine activity) andGO:0038145(macrophage
colony-stimulating factor signaling pathway) toGO:0061514(interleukin-34-mediated signaling
pathway), and acceptingGO:0061514; updatedgenes/human/IL21/IL21-ai-review.yamlto modify
GO:0007165(signal transduction) toGO:0038114(interleukin-21-mediated signaling
pathway), retainGO:0007259(cell surface receptor signaling pathway via JAK-STAT) as
ACCEPT, and modify receptor-binding rows (GO:0005126,GO:0005134) toGO:0005125
(cytokine activity); and updatedgenes/human/IL22/IL22-ai-review.yamlto modifyGO:0007165
(signal transduction) toGO:0140865(interleukin-22-mediated signaling pathway), retain
NEWGO:0007259(cell surface receptor signaling pathway via JAK-STAT), and modify
GO:0045518(interleukin-22 receptor binding) toGO:0005125(cytokine activity). - FASLG, CXCL8, and C5 gene reviews: updated
genes/human/FASLG/FASLG-ai-review.yamlto add
NEWGO:0036337(Fas signaling pathway,PMID:7826947) alongside existingGO:0008625
(extrinsic apoptotic signaling pathway via death domain receptors),GO:0005125(cytokine
activity), andGO:0005123(death receptor binding); created the full humanCXCL8review
(genes/human/CXCL8/CXCL8-ai-review.yaml), acceptingGO:0038112(interleukin-8-mediated
signaling pathway,IDA,PMID:8399143),GO:0008009(chemokine activity), andGO:0005153
(interleukin-8 receptor binding), modifying broader/sibling signaling terms (GO:0007165,
GO:0007186,GO:0035556,GO:0019722) toGO:0038112, modifyingGO:0005125(cytokine
activity) toGO:0008009, modifyingGO:0045236(CXCR chemokine receptor binding) to
GO:0005153, and removing mis-keyedGO:0016020(membrane,PMID:25411203, with
source_defects); and created the full humanC5review (genes/human/C5/C5-ai-review.yaml),
addingNEWGO:0038178(complement component C5a signaling pathway,PMID:36806352),
modifyingGO:0007166(PMID:10820279) andGO:0007186(PMID:8898085) toGO:0038178,
acceptingGO:0001664(G protein-coupled receptor binding) as core MF (and modifying
GO:0005102toGO:0001664), and removing (REMOVE) both the mis-curatedPINCTAS
GO:0008009(chemokine activity,PMID:10820279, withsource_defects) and the InterPro2GO
IEAGO:0004866(endopeptidase inhibitor activity). - C3, TSHB, CGA, GRP, NMB, and COL1A1 gene reviews (Tranche 4B): updated human
C3
(genes/human/C3/C3-ai-review.yaml) so that all four UniProtIDAGO:0008009(chemokine
activity) rows (PMID:342601previouslyREMOVE,PMID:37169960andPMID:37852260previously
MODIFY, andPMID:5778786previouslyUNDECIDED) are uniformlyREMOVEwithsource_defects
(WRONG_TERMwithREPOINTtoGO:0048018onPMID:37169960/PMID:37852260andDELETE_ROWon
PMID:342601/PMID:5778786), matchingC5andPTHR11412-review.yaml; created the full human
TSHB(genes/human/TSHB/TSHB-ai-review.yaml) andCGA(genes/human/CGA/CGA-ai-review.yaml)
reviews forGO:0038194(thyroid-stimulating hormone signaling pathway); created the full human
GRP(genes/human/GRP/GRP-ai-review.yaml) andNMB(genes/human/NMB/NMB-ai-review.yaml)
reviews forGO:0031989(bombesin receptor signaling pathway); and updated humanCOL1A1
(genes/human/COL1A1/COL1A1-ai-review.yaml) to addNEWICannotations and a second
core_functionsentry forGO:0048018(receptor ligand activity) andGO:0038063
(collagen-activated tyrosine kinase receptor signaling pathway). - EDN1, EDN3, GAL, GALP, PENK, and PDYN gene reviews (Tranche 4C): created the full human
EDN1
(genes/human/EDN1/EDN1-ai-review.yaml) andEDN3(genes/human/EDN3/EDN3-ai-review.yaml)
reviews forGO:0086100(endothelin receptor signaling pathway) andGO:0160135(phospholipase
C-activating endothelin receptor signaling pathway), accepting existingGO:0086100onEDN1,
addingNEWICGO:0160135onEDN1andNEWIDAGO:0086100,GO:0160135,GO:0031707,
andGO:0007204onEDN3, and refiningGO:0007166,GO:0007186,GO:0007267,GO:0023019,
GO:0035556, andGO:0160195onEDN1andGO:0007165,GO:0007166, andGO:0007267onEDN3
viaMODIFYtoGO:0086100andGO:0160135; created the full humanGAL
(genes/human/GAL/GAL-ai-review.yaml) andGALP(genes/human/GALP/GALP-ai-review.yaml) reviews
forGO:0090663(galanin-activated signaling pathway,NEWIConGALandNEWISSon
GALP) andGO:0005184(neuropeptide hormone activity,ACCEPTonGALandNEWISSon
GALP); and created the full humanPENK(genes/human/PENK/PENK-ai-review.yaml) andPDYN
(genes/human/PDYN/PDYN-ai-review.yaml) reviews forGO:0038003(G protein-coupled opioid receptor
signaling pathway) andGO:0031635(adenylate cyclase-inhibiting opioid receptor signaling
pathway), accepting existingGO:0038003onPENK, addingNEWICGO:0031635onPENKand
NEWIDAGO:0038003andNEWICGO:0031635onPDYN, and modifyingGO:0007165to
GO:0038003andGO:0031635onPENK. - PANTHER family reviews (
PTHR45836,PTHR11574,PTHR11304,PTHR11954,PTHR28606,
PTHR14356,PTHR48488,PTHR11471,PTHR12015,PTHR11412,PTHR11515,PTHR11509,
PTHR16866,PTHR24023,PTHR13874,PTHR16839,PTHR20950,PTHR11438): interpro/panther/PTHR45836/PTHR45836-review.yaml: thePTN002911633assessment notes that
its IBD should use the ligand-activity term; a newSUBFAMILY_ONLYassessment of
chemorepellent activity covers the four Slit subfamilies.interpro/panther/PTHR11574/PTHR11574-review.yaml:SOUNDnode assessments for
PTN002611905on its two IBD terms (GO:0005886plasma membrane,GO:0008284positive
regulation of cell population proliferation) andFAMILY_WIDEterm assessments for
GO:0005125(cytokine activity),GO:0038109(Kit signaling pathway),GO:0005173,
GO:0005886andGO:0008284; PAINT does not placeGO:0005125orGO:0038109at the node.interpro/panther/PTHR11304/PTHR11304-review.yaml:SOUNDnode assessments on
PTN000885159(GO:0046875ephrin receptor binding,GO:0048013ephrin receptor
signaling pathway,GO:0005886plasma membrane,GO:0007411axon guidance), noting
inassessment_reasonthat PAINT should also assertGO:0048018(receptor ligand
activity) atPTN000885159, together withFAMILY_WIDEterm assessments forGO:0048018
andGO:0048013.interpro/panther/PTHR11954/PTHR11954-review.yaml:SOUNDnode assessments on
PTN000237510(GO:0005576extracellular region,GO:0050178phenylpyruvate
tautomerase activity) andPTN000237513(GO:0005125cytokine activity), noting in
assessment_reasonand theFAMILY_WIDEterm assessment forGO:0035691(macrophage
migration inhibitory factor signaling pathway) that PAINT should also placeGO:0035691at
PTN000237513.interpro/panther/PTHR28606/PTHR28606-review.yaml:SOUNDnode assessments on
PTN002823014(GO:0005576extracellular region,GO:0005157macrophage
colony-stimulating factor receptor binding,GO:0008284positive regulation of cell
population proliferation,GO:0045651positive regulation of macrophage differentiation,
GO:0045657positive regulation of monocyte differentiation), noting inassessment_reason
and theFAMILY_WIDEterm assessments forGO:0005125(cytokine activity) andGO:0061514
(interleukin-34-mediated signaling pathway) that PAINT should also placeGO:0005125and
GO:0061514atPTN002823014.interpro/panther/PTHR14356/PTHR14356-review.yaml:SOUNDnode assessments on
PTN002682898, the node whose seeds span both subfamilies (GO:0001819positive regulation of cytokine production,GO:0050778
positive regulation of immune response),PTN002682897(includingGO:0005125cytokine
activity andGO:0005576extracellular region) andPTN007637558(GO:0045954positive
regulation of natural killer cell mediated cytotoxicity),FAMILY_WIDEterm assessment for
GO:0005125(cytokine activity) across IL-21 (PTHR14356:SF2) and IL-15 (PTHR14356:SF3)
subfamilies, andSUBFAMILY_ONLYterm assessments forGO:0038114(interleukin-21-mediated
signaling pathway onPANTHER:PTHR14356:SF2) andGO:0035723(interleukin-15-mediated
signaling pathway onPANTHER:PTHR14356:SF3).interpro/panther/PTHR48488/PTHR48488-review.yaml:SOUNDnode assessments on
PTN009232695(GO:0005125cytokine activity,GO:0005576extracellular region) and
UNRESOLVEDonGO:0050728(negative regulation of inflammatory response), plus a
FAMILY_WIDEterm assessment recommendingGO:0140865(interleukin-22-mediated signaling
pathway) atPTN009232695.interpro/panther/PTHR11471/PTHR11471-review.yaml:SOUNDnode assessments on
PTN000895255(GO:0005125cytokine activity,GO:0005576extracellular region,
GO:0007166cell surface receptor signaling pathway,GO:0043123positive regulation of
canonical NF-kappaB signal transduction) and onPTN001352146,PTN002607429,
PTN002607446andPTN008518640,TOO_DEEPonPTN000895255GO:2001238(positive
regulation of extrinsic apoptotic signaling pathway), andSUBFAMILY_ONLYterm assessments
forGO:0036337(Fas signaling pathway onPANTHER:PTHR11471:SF33) andGO:0008625
(extrinsic apoptotic signaling pathway via death domain receptors onSF33,SF27,
SF23).interpro/panther/PTHR12015/PTHR12015-review.yaml:SOUNDnode assessments on
PTN002564680(ELR+ CXC chemokines including CXCL8),PTN000245709(CC/XC chemokines),
PTN000428508(CXCL12), andPTN008302571(CXCL9/10/11),NEEDS_PRUNINGonPTN008532501
GO:0048245(eosinophil chemotaxis forSF103CCL4),FAMILY_WIDEterm assessments for
GO:0008009(chemokine activity) andGO:0070098(chemokine-mediated signaling pathway),
and aSUBFAMILY_ONLYterm assessment forGO:0038112(interleukin-8-mediated signaling
pathway onPANTHER:PTHR12015:SF200).interpro/panther/PTHR11412/PTHR11412-review.yaml:TOO_DEEPassessment onPTN000892454
GO:0004866(endopeptidase inhibitor activity, over-propagated into complement C3/C4/C5),
WRONG_NODEassessment onPTN008967461GO:0008009(chemokine activity, conflating
anaphylatoxins C3a/C5a with chemokines),SOUNDassessments onPTN002605305(C5) and
PTN002605320(C3), andSUBFAMILY_ONLYterm assessments forGO:0038178(complement
component C5a signaling pathway onPANTHER:PTHR11412:SF83) andGO:0004866(endopeptidase
inhibitor activity onSF165,SF182,SF92,SF116,SF133,SF170,SF174).interpro/panther/PTHR11515/PTHR11515-review.yamland
interpro/panther/PTHR11509/PTHR11509-review.yaml:SOUNDnode assessments onPTN000162063
(beta chains) andPTN002608947(alpha chainCGA),SCOPE_MISMATCHonPTN002608947
GO:0016914(follicle-stimulating hormone complex), andSUBFAMILY_ONLY/FAMILY_WIDE
term assessments scopingGO:0038194(thyroid-stimulating hormone signaling pathway) to
TSHB(PTHR11515:SF5),GPHB5(PTHR11515:SF14),CGA(PTHR11509:SF0), andGPHA2
(PTHR11509:SF5).interpro/panther/PTHR16866/PTHR16866-review.yaml:SOUNDnode assessments onPTN008565241
(GO:0005576,GO:0005184neuropeptide hormone activity,GO:0007218neuropeptide
signaling pathway),PTN002704034(NMB), andPTN002704045(GRP), and aSUBFAMILY_ONLY
term assessment scopingGO:0031989(bombesin receptor signaling pathway) toGRP
(PTHR16866:SF2) andNMB(PTHR16866:SF3).interpro/panther/PTHR24023/PTHR24023-review.yaml:SOUNDnode assessments onPTN001166351
(GO:0030020),PTN008390299(GO:0031012),PTN009074843(GO:0030199on the major
fibrillar collagen clade),PTN000615596(COL4A2), andPTN000615545(COL4A6), plus
SUBFAMILY_ONLYterm assessments forGO:0048018(receptor ligand activity) and
GO:0038063(collagen-activated tyrosine kinase receptor signaling pathway) acrossCOL1A1
(SF1082),COL1A2(SF568),COL2A1(SF58), andCOL3A1(SF604).interpro/panther/PTHR13874/PTHR13874-review.yaml:SOUNDnode assessments onPTN000356323
(GO:0005576extracellular region,GO:0005179hormone activity,GO:0031708endothelin B
receptor binding,GO:0003100regulation of systemic arterial blood pressure by endothelin,
GO:0006874intracellular calcium ion homeostasis,GO:0014826vein smooth muscle
contraction,GO:0045987positive regulation of smooth muscle contraction) andPTN002676936
(GO:0031707endothelin A receptor binding on theEDN1clade),FAMILY_WIDEterm
assessments forGO:0005179andGO:0005576, andSUBFAMILY_ONLYterm assessments for
GO:0086100(endothelin receptor signaling pathway) andGO:0160135(phospholipase
C-activating endothelin receptor signaling pathway) acrossEDN1(SF10),EDN2(SF9), and
EDN3(SF11).interpro/panther/PTHR16839/PTHR16839-review.yamland
interpro/panther/PTHR20950/PTHR20950-review.yaml:SOUNDnode assessments onPTN008359337
(GAL:GO:0005576,GO:0030141,GO:0043025,GO:0005184,GO:0007189,GO:0007218) and
PTN001463568(GALP:GO:0042595), plusFAMILY_WIDEterm assessments forGO:0005184
(neuropeptide hormone activity),GO:0090663(galanin-activated signaling pathway), and
GO:0005576(extracellular region).interpro/panther/PTHR11438/PTHR11438-review.yaml:SOUNDnode assessments onPTN000153716
(GO:0043025neuronal cell body,GO:0001515opioid peptide activity,GO:0031628opioid
receptor binding,GO:0007218neuropeptide signaling pathway,GO:0019233sensory perception
of pain),PTN002605991(PNOC:GO:0099013),PTN002606001(PENK:GO:0099013), and
PTN002606008(PDYN:GO:0097060,GO:0007270), plusFAMILY_WIDEterm assessments for
GO:0001515(opioid peptide activity),GO:0038003(G protein-coupled opioid receptor
signaling pathway),GO:0031635(adenylate cyclase-inhibiting opioid receptor signaling
pathway), andGO:0005576(extracellular region) acrossPENK(SF3),PDYN(SF4), and
PNOC(SF2).- Corpus count of receptor-specific binding terms in gene reviews: 820 annotation rows in
353 reviews (489 ACCEPT, 221 KEEP_AS_NON_CORE, 13 MODIFY), plus 162 core functions. Most common:
Notch binding (73), integrin binding (67), EGF receptor binding (36), ephrin receptor binding
(30), FGF receptor binding (29). Not yet acted on. - History records for every edit are under
history/.
Handoff
Done
- Ligand survey, gap check, triage and the relaxed-rule experiment, all rerunnable (below).
- Research on GO policy (sections 1 and 2) and the decisions in section 2.
- Modules:
netrin_signaling,slit_robo_signaling,kit_signaling(upgraded),
ephrin_receptor_signaling(upgraded),mif_signaling,il34_signaling,il21_signaling,
il22_signaling,death_receptor_apoptotic_signaling(upgraded),chemokine_signaling
(upgraded),c5a_signaling,tsh_signaling,bombesin_receptor_signaling,
collagen_ddr_signaling,neurotrophin_toll_signaling,endothelin_receptor_signaling,
galanin_signaling,opioid_receptor_signaling. - Gene reviews: NTN1, NTN3, KITLG, kitlga, EFNB1, MIF, IL34, IL21, IL22, FASLG, CXCL8, C5, C3,
TSHB, CGA, GRP, NMB, COL1A1, DDR1, Ddr, NT1, spz5, Toll-6, kek6, EDN1, EDN3, GAL, GALP, PENK,
PDYN. - Family reviews: PTHR45836, PTHR11574, PTHR11304, PTHR11954, PTHR28606, PTHR14356, PTHR48488,
PTHR11471, PTHR12015, PTHR11412, PTHR11515, PTHR11509, PTHR16866, PTHR24023, PTHR13874,
PTHR16839, PTHR20950, PTHR11438. - Report page: report/ligand-gap-report.html
(human, fly and fission yeast snapshot; also published as the Ligand gap report artifact).
It predates the GPCR scope and the other species, so its counts are lower than section 3.
Next steps
- More modules, pan-species, ligand step first, using the decisions in section 2. All receptor
and ligand members of the collagen-DDR and fly Toll-6/7 neurotrophin modules now have gene
reviews (DDR1, fly Ddr, NT1, spz5, Toll-6 and kek6 were added after the modules). The NT1 and
spz5 reviews move the ligands onto neurotrophin signaling pathway, and the Toll-6 review removes
the Roundabout-binding IBA from the Slit PAINT node. The fly Ddr review predicts a pseudokinase
and gives Ddr's core role as wrapping-glia axon ensheathment, so fly Ddr was dropped as a module
representative; human COL1A1 now carries a receptor-ligand-activity core function for DDR
signaling, while the other collagen reviews (COL1A2, COL2A1, COL3A1, COL4A1, COL10A1) do not yet.
Remaining GPCR/hormone queue: angiotensin signaling (AGT), CCL19 signaling, APOA1 signaling (plus
remaining ligand paralogsEDN2,PNOC, andPOMCfor the endothelin and opioid modules).
Several human gaps (VEGFR-1/3, FGFR, Fas, CXCL8) already have modules with the
ligand; they need the hole-filling run, not new modules. - Module-driven hole filling. Replace
curated/expected_ligands.yamlwith the modules: an
annotation oracle forsrc/ai_gene_review/module_logic.pythat resolves each ligand annoton's
family to members per species (PANTHER membership, as in
projects/PATHWAY_SATISFIABILITY/taxon_absent_component/) and asks GOA whether they carry the
module's pathway term. Unfilled ligand steps are the gaps. - Binding-term MODIFY batch over the 820 rows and 162 core functions: propose a replacement
per row (ligand → receptor ligand activity or child; non-ligand → its actual activity; skip
adaptor terms), for curator review. Consider adding the rule to CLAUDE.md. - GO issues to draft for C. Mungall: the outdated comment on signaling receptor binding;
ligands annotated only with receptor-specific binding terms; PomBase's pheromone convention
(ligand and receptor as regulators of the MAPK cascade) and budding yeast pheromones missing
from the pathway; optionally Hedgehog/Patched on #14275. - VEGFA review inconsistency, unresolved: it REMOVEs cellular response to vascular
endothelial growth factor stimulus ("VEGFA is the ligand, not the responder") while ACCEPTing
vascular endothelial growth factor signaling pathway, which is part_of that response.
Decide alongside #15477; no edit was made. - Check the fly over-annotation (O) calls against data before acting on them.
How to rerun
# data (GAFs + go-basic.obo) into the git-ignored .cache/ligands_in_signaling
projects/LIGANDS_IN_SIGNALING/scripts/fetch_data.sh
# gap check for all seven organisms, then the relaxed-rule variant for human and fly
uv run python projects/LIGANDS_IN_SIGNALING/scripts/ligand_gap_check.py --out projects/LIGANDS_IN_SIGNALING/results
uv run python projects/LIGANDS_IN_SIGNALING/scripts/ligand_gap_check.py --out projects/LIGANDS_IN_SIGNALING/results --orgs human fly --or-receptor-binding
# triage; writes results/triage.json and results/RESULTS.md
uv run python projects/LIGANDS_IN_SIGNALING/scripts/triage.py --results projects/LIGANDS_IN_SIGNALING/results
# QuickGO survey of textbook ligands (network; a few minutes)
uv run python projects/LIGANDS_IN_SIGNALING/scripts/survey/ligand_pathway_survey.py --out projects/LIGANDS_IN_SIGNALING/results/ligand_survey.json
Known issues
- Module validator: no errors in the eleven modules, but PANTHER family membership is not
checked. The validator reports every representative member as "not in the PANTHER member index
... so family membership was not checked". Checked instead against each member's UniProt
DR PANTHERlines: the families agree for the netrin, Slit-Robo, Kit, MIF, chemokine and C5a
modules. The exceptions are pre-existing steps outside the ligand work. In
ephrin_receptor_signaling.yaml, EPHA2 and EPHB4 sit underPTHR24416, but UniProt places them
inPTHR46877. Indeath_receptor_apoptotic_signaling.yaml, CASP8 sits underPTHR10454, but
UniProt places it inPTHR48169. Some STAT3, STAT1 and GRB2 subfamily ids in the IL modules
have no matching subfamily in UniProt, which lists only the family. These are flagged here and
not changed. - Other advisory warnings:
PTN008501429(netrin) seed overlap not checked, because its IBD seeds
carry no UniProtKB accession.slit_robo_signaling.yaml:PTN002911633attests only
GO:0008201andGO:0048495, not the step's terms (intentional, Decision 2), and a
FAMILY_SCOPE_RESTRICTEDwarning saysGO:0045499isSUBFAMILY_ONLY. The ephrin
PTN000885159term mismatch is not flagged by the validator. The remaining warnings are
PTN-aspect and family-review-conformance warnings inkit_signaling,il21_signaling,
il34_signaling,death_receptor_apoptotic_signaling,chemokine_signalingandc5a_signaling. tests/test_bioreason_benchmark_policy.py::test_argo95_exact_goa_reads_the_declared_baseline_commit
fails on main as well; unrelated to this work.